Abstract | UNLABELLED:
Neuroinflammation is thought to contribute to the pathogenesis and maintenance of temporal lobe epilepsy, but the underlying cell and molecular mechanisms are not fully understood. The P2X7 receptor is an ionotropic receptor predominantly expressed on the surface of microglia, although neuronal expression has also been reported. The receptor is activated by the release of ATP from intracellular sources that occurs during neurodegeneration, leading to microglial activation and inflammasome-mediated interleukin 1β release that contributes to neuroinflammation. Using a reporter mouse in which green fluorescent protein is induced in response to the transcription of P2rx7, we show that expression of the receptor is selectively increased in CA1 pyramidal and dentate granule neurons, as well as in microglia in mice that developed epilepsy after intra-amygdala kainic acid-induced status epilepticus. P2X7 receptor levels were increased in hippocampal subfields in the mice and in resected hippocampus from patients with pharmacoresistant temporal lobe epilepsy. Cells transcribing P2rx7 in hippocampal slices from epileptic mice displayed enhanced agonist-evoked P2X7 receptor currents, and synaptosomes from these animals showed increased P2X7 receptor levels and altered calcium responses. A 5 d treatment of epileptic mice with systemic injections of the centrally available, potent, and specific P2X7 receptor antagonist JNJ-47965567 (30 mg/kg) significantly reduced spontaneous seizures during continuous video-EEG monitoring that persisted beyond the time of drug presence in the brain. Hippocampal sections from JNJ-47965567-treated animals obtained >5 d after treatment ceased displayed strongly reduced microgliosis and astrogliosis. The present study suggests that targeting the P2X7 receptor has anticonvulsant and possibly disease-modifying effects in experimental epilepsy. SIGNIFICANCE STATEMENT:
|
Authors | Alba Jimenez-Pacheco, Miguel Diaz-Hernandez, Marina Arribas-Blázquez, Amaya Sanz-Rodriguez, Luis A Olivos-Oré, Antonio R Artalejo, Mariana Alves, Michael Letavic, M Teresa Miras-Portugal, Ronan M Conroy, Norman Delanty, Michael A Farrell, Donncha F O'Brien, Anindya Bhattacharya, Tobias Engel, David C Henshall |
Journal | The Journal of neuroscience : the official journal of the Society for Neuroscience
(J Neurosci)
Vol. 36
Issue 22
Pg. 5920-32
(06 01 2016)
ISSN: 1529-2401 [Electronic] United States |
PMID | 27251615
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2016 the authors 0270-6474/16/365921-13$15.00/0. |
Chemical References |
- Aif1 protein, mouse
- Calcium-Binding Proteins
- JNJ-47965567
- Microfilament Proteins
- Nerve Tissue Proteins
- Piperazines
- Platelet Aggregation Inhibitors
- Purinergic P2X Receptor Antagonists
- Receptors, Purinergic P2X7
- enhanced green fluorescent protein
- Green Fluorescent Proteins
- Niacinamide
- 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate
- Adenosine Triphosphate
|
Topics |
- Adenosine Triphosphate
(analogs & derivatives, pharmacology)
- Adolescent
- Adult
- Animals
- Brain
(metabolism, ultrastructure)
- Calcium-Binding Proteins
(metabolism)
- Disease Models, Animal
- Epilepsy, Temporal Lobe
(complications, drug therapy, pathology)
- Gene Expression Regulation
(drug effects, physiology)
- Gliosis
(drug therapy, etiology)
- Green Fluorescent Proteins
(genetics, metabolism)
- Humans
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Transgenic
- Microfilament Proteins
(metabolism)
- Middle Aged
- Nerve Tissue Proteins
(metabolism)
- Niacinamide
(analogs & derivatives, metabolism, pharmacology, therapeutic use)
- Piperazines
(metabolism, pharmacology, therapeutic use)
- Platelet Aggregation Inhibitors
(pharmacology)
- Purinergic P2X Receptor Antagonists
(pharmacology, therapeutic use)
- Receptors, Purinergic P2X7
(genetics, metabolism)
- Seizures
(drug therapy, etiology)
- Up-Regulation
(drug effects, physiology)
- Young Adult
|